Tonix Pharmaceuticals Holding Corp. Price & Performance (TNXP)

Tonix Pharmaceuticals presented new data on its single-dose mpox vaccine, TNX-801, at the World Vaccine Congress in Washington. The company also highlighted its fibromyalgia candidate TNX-102 SL, which has a key FDA decision date in August. These developments underscore Tonix's focus on infectious disease and CNS disorders.12

Tonix Pharmaceuticals stock closed at $17.19 after a 1% gain, but technical signals remain negative with a forecasted short-term decline of nearly 13%. Despite some buy signals, falling volume and persistent volatility point to continued risk for investors in the coming weeks.34

Tonix Pharmaceuticals reported revenue of $10.09 million for 2024, a nearly 30% increase year-over-year. However, net losses deepened to $130 million. While analysts rate the stock as a strong buy, long-term returns remain uncertain due to ongoing financial pressures and market volatility.56